MorningStar Laboratories (MSL) develops and provides precision diagnostic testing focused on vascular inflammation and unmet clinical needs. The laboratory is CLIA certified and CAP accredited. Its flagship offering, SmartVascular Dx (SVDx), is described as NID-validated and is used by more than 2,400 physicians; the company reports that over 200,000 tests have been performed across a diverse population.

SVDx is designed to help physicians detect chronic, subclinical vascular inflammation that conventional tests may overlook. It measures seven protein biomarkers associated with arterial injury and provides information about vascular inflammatory activity, endothelial-associated biomarker patterns, and factors linked to conditions such as dyslipidemia, hypertension, and diabetes. Results can help physicians assess vascular health, consider early therapeutic decisions, and develop personalized treatment plans. Repeat testing can also support monitoring over time through a progress report.

MorningStar Laboratories provides physician-facing laboratory reports, test information, sample reports, FAQs, and support for providers, including enrollment, ordering, laboratory information system access, and specimen collection kit requests. The company encourages patients to discuss SVDx with their doctor.